The
increasing need for animal alternatives in medical research and growing
government funds and grants for studies are the prime factors strengthening the
organ-on-chip market, globally. In 2017, the market generated a revenue
of $11.0 million, and it is predicted to witness a 40.1% CAGR during the
forecast period (2018–2025). Organ-on-chip is a 3D microfluidic cell culture
chip, developed to simulate the mechanical and natural physiological forces
that cells are subject to inside the human body. These chips are integrated with
living human cells as well as tiny fluidic channels to propagate air and blood flow.
Get report sample at: http://bit.ly/2Go5j5o
Based
on type, the organ-on-chip market is broadly classified into liver,
heart, lung, kidney, and intestine-on-chip. Among these, in 2017, the liver-on-chip
classification dominated the market in terms of revenue, and it is expected to
exhibit the fastest growth with more than 45.0% CAGR during the 2018–2025
period. The surging incidents of chronic liver disease and rising research and
development activities for therapeutic interventions are the major factors
responsible for the growth of this classification.
The
increasing collaboration among the key players and rising number of product
launches are helping in the development of the organ-on-chip market. For
instance, in October 2017, Charles River
Laboratories International Inc. (Charles River) permitted InSphero AG to license
its patient-derived xenograft (PDX) tumors. Furthermore, the company was to use
the proprietary 3D cell culture technology of InSphero to further complement
and expand its pre-clinical services, utilizing the in-vitro 3D
InSight Tumor Microtissues obtained from its current PDX tumors.
Thus,
the growing need for alternative models for medical research studies is
expected to boost the organ-on-chip market progress during the forecast
period. Further, the increasing government funding is helping the market
players conduct more research activities. Government agencies such as the National
Institutes of Health offers grants to facilitate the research programs. For instance, in July 2017, Emulate Inc. declared it had been granted an
undisclosed amount to utilize its human Brain-Chip system to create a fully
automated research platform for carrying out experiments on the International
Space Station.
Hence, the rising demand
for alternative models for medical research and growing government support are accelerating
the market growth.
0 Comments